Artelo Biosciences (ARTLW) Stock Analysis

What Artelo Biosciences does

Artelo Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing and commercializing therapeutic agents that interact with the endocannabinoid system. The company's portfolio of drug candidates features ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is currently undergoing Phase 1b/2a clinical trials for the management of anorexia linked to cancer. Another promising candidate is ART12.11, a synthetic cannabidiol cocrystal being explored for its potential in treating inflammatory bowel disease and post-traumatic stress disorder (PTSD). Additionally, ART26.12, a fatty acid binding protein 5 inhibitor, is in development to address breast and prostate cancer, neuropathic and nociceptive pain, and various anxiety disorders, including PTSD. The company, initially incorporated in 2011 as Reactive Medical, Inc., was rebranded as Artelo Biosciences, Inc. in April 2017 and is headquartered in Solana Beach, California.

Key metrics

ETFs linked to ARTLW

Broad-market and Healthcare sector ETFs an investor holding Artelo Biosciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ARTLW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Artelo Biosciences?

Artelo Biosciences trades under the ticker ARTLW on NASDAQ.

Which exchange is ARTLW listed on?

ARTLW is listed on NASDAQ.

What sector does Artelo Biosciences operate in?

Artelo Biosciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ARTLW in a portfolio?

PortView shows ARTLW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.